Bank of New York Mellon Corp Takes $884,000 Position in Metsera Inc. (NASDAQ:MTSR)

Key Points

• Bank of New York Mellon Corp acquired a new stake in Metsera Inc., purchasing 32,494 shares valued at approximately $884,000.
• Metsera's stock rose by 5.8%, currently priced at $34.89, with a 52-week range between $12.30 and $47.40.
• Analysts maintain a consensus rating of "Buy" for Metsera, with price targets reaching as high as $65.00.

Bank of New York Mellon Corp purchased a new stake in Metsera Inc. (NASDAQ:MTSR - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 32,494 shares of the company's stock, valued at approximately $884,000.

Metsera Stock Up 5.8%

MTSR stock opened at $34.89 on Friday. The stock's fifty day simple moving average is $32.59. Metsera Inc. has a 52-week low of $12.30 and a 52-week high of $47.40.

Metsera (NASDAQ:MTSR - Get Free Report) last released its quarterly earnings results on Monday, July 28th. The company reported ($0.66) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Wells Fargo & Company initiated coverage on Metsera in a report on Friday, June 20th. They issued an "overweight" rating and a $65.00 target price for the company. Guggenheim boosted their price target on shares of Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a research report on Tuesday, June 10th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $55.00.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.